When I first read about what scientists at the University of Bristol and NHS Blood and Transplant were doing, it was striking: a massive amount of donated blood quietly expires before it ever reaches a patient. It doesn’t save lives. It gets thrown away.
But here’s the extraordinary twist: those same researchers figured out how to take that discarded, expired blood and use the living stem cells hiding inside it to grow billions of fresh red blood cells in the laboratory. And in November 2022, they transfused some of those lab-grown cells into real human volunteers. It worked. No serious side effects. Cells survived longer than standard donated blood.
This article is my deep-dive into that science — written for curious readers who want to understand the actual mechanism, the real clinical results, and what realistically comes next. No jargon wall. No overhyping. Just the full picture.
Section 01 — The Problem Why the World Never Has Enough Blood
Before we get into how the technology works, let’s sit with the scale of the problem it is solving. The blood shortage is not a crisis that appears occasionally in news headlines — it is a permanent, structural feature of global healthcare that most healthy people never have to think about.
| The Blood Supply Reality | What It Actually Means |
|---|---|
| Shelf life of donated red blood cells | Just 42 days — every unit must be discarded after this point, regardless of whether it was needed |
| Blood wasted annually | Millions of units thrown away worldwide — a staggering, invisible waste of what could be a life-saving resource |
| Rare blood type patients | People with Rh-null (“golden blood”) may wait months or years for a single compatible match — some simply cannot receive safe transfusions at all |
| Sickle cell disease patients | Need transfusions every 3–4 weeks for life. After many transfusions, their immune systems develop antibodies to minor blood antigens, making compatible blood progressively harder to find |
| The fundamental problem | Blood supply depends entirely on volunteer goodwill. It is unpredictable, geography-dependent, and always racing against a 42-day clock |
I learned something uncomfortable while researching this piece: blood collection tends to surge during donation campaigns and drop between them. A hospital that receives more blood than it immediately needs during a high-turnout drive may find itself discarding perfectly healthy units as the 42-day window closes — even while a patient somewhere else goes without. I had always assumed my donations went straight to someone who needed them. Reading the actual logistics was a sobering correction. Which made the solution these scientists found feel all the more elegant.
Section 02 — The Discovery The Insight That Changes Everything
For years, scientists understood a quiet fact about blood that most people don’t know: ordinary donated blood contains not just mature red blood cells, but also a small number of stem cells — specifically a type called erythroid progenitor cells. These are immature master cells that have already “decided” they are going to become red blood cells — they just haven’t finished the journey yet.
When blood expires and gets thrown away, those stem cells are thrown away with it. The key question researchers at Bristol asked was simple but brilliant: what if we didn’t throw them away?
By isolating erythroid progenitor cells from donated blood — including blood that has already exceeded its transfusion shelf life — and culturing them in precisely controlled laboratory conditions, researchers demonstrated that a single discarded unit of blood contains enough stem cells to theoretically produce 50,000 units of fresh, fully functional laboratory-grown red blood cells.
The discard pile becomes the starting material. The 42-day problem becomes, in principle, solved. Waste is transformed into resource — at a 50,000:1 ratio.
Section 03 — The Process How You Actually Grow Blood in a Laboratory: Step by Step
The process is genuinely fascinating — and less science-fiction than it sounds. Here is exactly what happens between “expired blood arrives from the blood bank” and “lab-grown cells are ready for a patient”:
-
1Collect Discarded Expired Blood
Blood that has reached its 42-day shelf life and would normally be disposed of is collected before final discard. This raw material has zero current value to the medical system — making it essentially free to acquire.
collecting vegetable trimmings from a restaurant kitchen — material that was always going in the bin, now sent to make broth instead
-
2Isolate the Stem Cells (Erythroid Progenitors)
Using magnetic bead separation and density centrifugation, scientists physically separate the rare stem cells from the far more abundant mature red blood cells. These progenitors carry specific protein markers on their surface — a kind of molecular shipping label — that allow precise identification and extraction.
sifting through a pile of ordinary coins to pick out the rare gold pieces hiding among them — except using magnets and science instead of fingers
-
3Culture and Multiply
Isolated stem cells go into a culture medium containing specific growth factors, nutrients, and hormones — most importantly erythropoietin (EPO), the same hormone the kidneys naturally produce to signal bone marrow to make more red blood cells. Under these conditions, cells begin doubling every 24–48 hours.
planting a single seed in perfectly mixed soil, with exactly the right light and water, and watching it multiply into thousands of new plants over days
-
4Trigger Differentiation
Once enough cells exist, the culture conditions are deliberately changed to instruct the stem cells to begin maturing — to start the journey toward becoming fully formed red blood cells. This replicates what happens naturally and continuously inside human bone marrow cavities.
switching a training program from general education to specialist medical residency — turning students into doctors
-
5Enucleation — Expelling the Nucleus
Unlike almost every other cell in the human body, mature red blood cells contain no nucleus. This is intentional — removing the nucleus allows the cell to be completely packed with oxygen-carrying hemoglobin and to flex through capillaries narrower than its own width. Lab-grown cells must also expel their nuclei (a process called enucleation) to become genuine, functional red blood cells.
emptying a delivery bag of everything except the one critical package it was designed to carry
-
6Rigorous Quality Testing
Every batch is exhaustively tested for oxygen-carrying capacity, cell flexibility, correct size and shape, surface protein expression, and contamination. Lab-grown cells must meet identical standards to conventionally donated blood before any clinical application is permitted.
final quality control inspection on a factory floor — nothing ships until it passes every test
-
7Transfusion
Verified, quality-cleared lab-grown red blood cells are packaged for clinical use. They are biologically indistinguishable from naturally produced cells, carry the blood type of the original donor, and the recipient’s immune system has no reason to react — because these are real human red blood cells, not imitations.
delivering a freshly manufactured, quality-inspected product directly to the person who ordered it
Section 04 — The Science Key Terms Explained in Plain English
Science writing about this topic is full of terminology that sounds intimidating but is actually quite logical once you break it down. Here are the terms that matter most:
| Term | What It Is | Why It Matters Here |
|---|---|---|
| Red Blood Cell (RBC) | A disc-shaped, nucleus-free cell packed with hemoglobin. Its entire purpose: carry oxygen from your lungs to every cell in your body, then carry CO₂ back out. | The end product — what scientists are growing at scale |
| Erythroid Progenitor Cell | A stem cell that has already committed to becoming a red blood cell but hasn’t fully matured yet. Found in small numbers in circulating blood. | The raw material — extracted from discarded blood and multiplied into billions of mature RBCs |
| Hemoglobin | The protein inside red blood cells that physically binds to oxygen molecules. Each red blood cell contains roughly 270 million hemoglobin molecules. It’s also why blood is red. | The functional cargo — lab-grown cells must produce sufficient hemoglobin to be medically useful |
| Erythropoietin (EPO) | A hormone produced by the kidneys that signals bone marrow to make more red blood cells. Famous (and infamous) in sports doping for dramatically boosting red cell production. | Added to culture medium to drive rapid stem cell multiplication and maturation |
| Enucleation | The process by which a maturing red blood cell ejects its own nucleus — unique to red blood cells and essential for maximum hemoglobin capacity and capillary flexibility. | The critical final developmental step — cells that don’t enucleate cannot be used clinically |
| Reticulocyte | An immature red blood cell that has expelled its nucleus but isn’t fully mature. Makes up about 1% of normal blood. Completes maturation within 1–2 days in the bloodstream. | The form in which lab-grown cells are transfused — final maturation happens inside the patient’s own body |
Section 05 — The Trial The World’s First Human Clinical Trial — What Actually Happened
The RESTORE Trial — University of Bristol & NHS Blood and Transplant
In November 2022, the world’s first human clinical trial of laboratory-manufactured red blood cells took place in the United Kingdom. Conducted by the University of Bristol in partnership with NHS Blood and Transplant, the RESTORE trial transfused small quantities of lab-grown red blood cells into healthy adult volunteers and tracked how those cells performed inside the human body.
The safety results were clear: no serious adverse events were reported in any participant.
But the finding that surprised even the researchers was this: lab-grown cells survived in the bloodstream for approximately 28–29 days — significantly longer than the average lifespan of cells from a standard donated blood unit near the end of its 42-day shelf life.
The reason is logical once you understand it. A standard bag of donated blood contains a mixed population of cells — some freshly made by the donor’s bone marrow just before donation, others older, approaching the end of their natural lifespan. The older cells die quickly after transfusion, dragging down the average useful life of the whole unit. Lab-grown blood contains only uniformly young, freshly made cells — every single one produced at the same time. Younger cells last longer and carry oxygen more efficiently.
Serious Adverse Events: Zero
Safety: Confirmed
Lead Institutions: University of Bristol + NHS
Status: World First Human Transfusion of Lab-Grown RBCs
For a patient with sickle cell disease who requires a transfusion every 3–4 weeks for their entire life, extending how long each transfusion’s cells remain functional could mean fewer transfusions needed per year. That cascade effect matters enormously: fewer transfusions means less iron accumulation in the body, reduced risk of developing immune antibodies that make future transfusions dangerous, and a measurably better quality of daily life. The clinical implication is far from trivial.
Section 06 — The Difference Why This Approach Succeeds Where Others Failed
Scientists have been attempting to create artificial blood for over half a century. Every previous approach either failed in clinical trials or never made it out of the laboratory. Here is a clear-eyed comparison:
Hemoglobin-Based Oxygen Carriers
Free hemoglobin extracted from red blood cells and modified chemically. Multiple clinical trials — all stopped early. Free hemoglobin outside a red blood cell is toxic, causing kidney damage and cardiovascular events.
Perfluorocarbon Emulsions
Synthetic fluorinated compounds that dissolve oxygen. Short shelf life, required patients to breathe high-concentration oxygen to function, limited capacity, side effects in trials.
Encapsulated Nano Hemoglobin
Hemoglobin packaged inside synthetic nano-scale capsules mimicking red cells. Extraordinarily expensive, immune recognition problems, never reached human trials.
Stem Cell–Grown Real Red Blood Cells
Actual human red blood cells grown from actual human stem cells. The patient’s immune system cannot distinguish them from naturally produced cells — because they are naturally produced cells. Just grown in a different location.
The fundamental distinction: every previous approach tried to imitate what red blood cells do, using synthetic chemistry. This approach doesn’t imitate anything. It simply grows the real biological product in a controlled laboratory environment instead of inside a bone marrow cavity. There is nothing for the immune system to reject — because the product is human, properly formed, and biologically complete.
Section 07 — Who Benefits The Patients This Technology Could Transform
This technology is not intended to replace all blood donation overnight — and realistic projections don’t suggest it will. But for specific patient populations, it represents something the current system genuinely cannot provide.
Sickle Cell Disease Patients
Need transfusions every 3–4 weeks for life. Repeated transfusions cause immune sensitization — making compatible blood progressively harder to find. Lab-grown blood from a single matched donor can be multiplied without limit, eliminating this escalating crisis.
Thalassaemia Patients
Similarly dependent on frequent lifelong transfusions. Mismatched blood carries serious immune risk. Perfectly matched, endlessly reproducible supply removes both the shortage and the danger.
Rare Blood Type Patients
Rh-null (“golden blood”) patients may have only dozens of compatible donors worldwide. One compatible donor’s expired blood can now be multiplied into years’ worth of their personal supply.
Low-Income Countries
Many nations lack safe, consistent blood donation infrastructure. Manufactured blood is tested, consistent, and supply-predictable — potentially saving millions of lives where donation programs cannot reliably operate.
Section 08 — The Challenges What Still Stands Between the Lab and Your Hospital
The science is proven. The first human trial succeeded. But significant engineering and regulatory challenges remain before this operates at meaningful scale:
| Challenge | Why It Matters | The Path Forward |
|---|---|---|
| 💰 Manufacturing Cost | Producing one unit of lab-grown blood currently costs far more than collecting donated blood. Culture media, growth factors, and bioreactor systems are expensive at research scale. | Automation, industrial bioreactors, and synthetic biology to produce growth factors cheaply. Costs are dropping rapidly as the field matures — following the same curve as insulin and monoclonal antibody manufacturing. |
| 📦 Production Volume | A single adult transfusion requires 1–2 units. The world needs over 100 million units annually. Current lab methods produce small research quantities. | Industrial-scale bioreactor systems — the same technology behind insulin and vaccine production — are being specifically adapted for red blood cell manufacturing. |
| ⚙️ Enucleation Efficiency | Not all cultured cells successfully expel their nuclei. Cells that fail to enucleate cannot be transfused, reducing yield and raising cost per usable unit. | Optimizing culture conditions and adding macrophage co-cultures (immune cells that assist nucleus expulsion) to push enucleation rates toward 100%. |
| 📋 Regulatory Framework | Lab-manufactured blood is a fundamentally new category of medical product. No complete regulatory approval pathway currently exists in most countries for this class of item. | UK MHRA and EU EMA are actively building approval frameworks. RESTORE trial data feeds directly into this process. First specialist approvals expected before 2030. |
Section 09 — The Timeline Realistic Expectations: When Does This Reach Patients?
-
✅ November 2022 — Achieved
World’s First Human Transfusion
RESTORE trial: lab-grown red blood cells transfused into healthy human volunteers. Safety confirmed. Cells survived longer than standard donated blood. No serious adverse events.
-
🔄 2024–2027 — In Progress
Expanded Clinical Trials + Regulatory Submissions
Larger trials in sickle cell and thalassaemia patient populations. Manufacturing process optimization. First submissions to UK MHRA and EU EMA for regulatory review.
-
🔵 2027–2032 — Planned
First Regulatory Approvals — Rare and Specialist Patients
Initial approvals for highly alloimmunized patients and extreme rare blood type cases. Small-scale clinical production begins in licensed facilities in the UK and EU.
-
🌠 2032–2040 — Vision
Industrial-Scale Manufacturing
Cost-competitive with donated blood for specialist applications. Broader patient access established. Lab-grown blood becomes a standard clinical option for defined therapeutic contexts.
I’ll admit: when I first saw the 2040 end of that timeline, my enthusiasm dimmed a little. But then I recalculated. The RESTORE trial happened in 2022. That means in under three years from laboratory proof-of-concept to actual human transfusion. The distance from “it works in a dish” to “it works in a person” closed shockingly fast. If the manufacturing scale-up follows a similar trajectory, first specialist patient approvals before 2030 feel genuinely plausible — not wishful thinking. Watching this field right now feels a bit like watching gene therapy in its early years. Slow, then suddenly everywhere.
Frequently Asked Questions Everything Readers Ask Most
Key Takeaways — What You Should Remember
-
01
Scientists can extract living stem cells from discarded, expired donated blood and grow them into billions of fresh, functional red blood cells — turning medical waste into a potential solution to the chronic global blood shortage. -
02
The world’s first human clinical trial (RESTORE, November 2022, UK) confirmed that lab-grown blood is safe to transfuse, and that lab-grown cells survive longer inside the body than standard donated blood — because every cell in the batch is uniformly young. -
03
Unlike every previous artificial blood attempt — all of which tried to imitate red blood cells with synthetic materials — this technology grows genuine human red blood cells from genuine human stem cells. There is nothing artificial about the end product. -
04
The patients who stand to benefit first and most are people with sickle cell disease, thalassaemia, and ultra-rare blood types — people for whom the conventional donated blood system is chronically inadequate and increasingly dangerous to use. -
05
Manufacturing cost and scale remain the primary barriers — but both are engineering problems, not fundamental scientific ones. First specialist patient approvals are realistically targeted within this decade. Blood donation remains essential and is not under threat of replacement.
About the Author
